Battelle has been selected for a $59 million contract from the US Army Joint Program Executive Office for Chemical and Biological to research and develop vaccines and therapeutics for biological and chemical threats.
The five-year contract was awarded through OASIS, the General Service Administration’s newest contracting vehicle open to all Federal Government agencies worldwide.
Headquartered in Columbus, Battelle serves the national security, health and life sciences, and energy and environmental industries. The company has conducted research designed to protect the military and general public from dangerous infectious disease and chemical threats.
Battelle is recognized for its technical expertise, and for as being flexible, efficient and responsive.
This latest contract provides for the development of vaccines for potentially weaponized viruses such as plague, botulinum, equine encephalitis, and filovirus, and medical countermeasures against multiple nerve agents and poisonous toxins used in chemical warfare.
"We’re proud of the work we do at Battelle to protect people from threats like the Ebola and Zika viruses or ricin," said Julie Swick, general manager for Battelle’s Life Sciences Research group. "Our dedicated employees come into work every day knowing they are contributing solutions to important, worldwide problems."
